KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of GoodwillAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)DivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bausch Health Companies (BHC) Free Cash Flow (2016 - 2025)

Bausch Health Companies (BHC) has disclosed Free Cash Flow for 17 consecutive years, with $403.0 million as the latest value for Q4 2025.

  • Quarterly Free Cash Flow fell 18.59% to $403.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.0 billion through Dec 2025, down 20.4% year-over-year, with the annual reading at $1.0 billion for FY2025, 20.4% down from the prior year.
  • Free Cash Flow hit $403.0 million in Q4 2025 for Bausch Health Companies, up from $314.0 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of $501.0 million in Q3 2021 to a low of -$1.3 billion in Q3 2022.
  • Historically, Free Cash Flow has averaged $164.5 million across 5 years, with a median of $266.0 million in 2023.
  • Biggest YoY gain for Free Cash Flow was 857.41% in 2022; the steepest drop was 362.87% in 2022.
  • Year by year, Free Cash Flow stood at -$54.0 million in 2021, then surged by 857.41% to $409.0 million in 2022, then dropped by 28.61% to $292.0 million in 2023, then skyrocketed by 69.52% to $495.0 million in 2024, then fell by 18.59% to $403.0 million in 2025.
  • Business Quant data shows Free Cash Flow for BHC at $403.0 million in Q4 2025, $314.0 million in Q3 2025, and $190.0 million in Q2 2025.